EBOS Group Ltd. reported stronger fiscal 2026 results and a constructive outlook for fiscal 2027, lifting shares in Australia. The healthcare and animal care distributor’s stock rose 8.28% on Wednesday to close at A$19.74, after the company forecast higher underlying EBITDA alongside a maintained dividend.
Key takeaways
- Shares climbed 8.28% in Australia to A$19.74 after EBOS posted higher fiscal 2026 earnings and a firmer fiscal 2027 outlook.
- Catalyst: EBOS guided underlying EBITDA for fiscal 2027 to A$635 million to A$655 million, supported by growth across core divisions.
- Dividend maintained: Directors declared a NZ 61.5 cents per share final dividend, matching the prior year.
- Operational drivers: Management pointed to network utilisation, productivity improvements, retail pharmacy expansion and animal care growth.
- Capital intensity ease: The company expects lower capital expenditure after completing a four-year distribution centre renewal programme.
What drove the move
EBOS said fiscal 2027 performance should build on recent momentum, with underlying EBITDA expected to rise to between A$635 million and A$655 million. The company attributed the outlook to higher network utilisation and productivity across Symbion & Healthcare Distribution, earnings expansion in Retail Pharmacy Brands, therapy and geographic expansion in Medical Technology, and new product and customer growth within Animal Care.
In addition to operational targets, EBOS flagged a shift that may support cash generation: the company expects lower capital expenditure following completion of its four-year distribution centre renewal program. That change is important for investors monitoring how much of earnings translate into free cash flow as the company moves past a multi-year build phase.
Fiscal 2026 results and payout
EBOS reported earnings of A$225.19 million for fiscal 2026, up from A$215.14 million last year. Earnings per share were 109.8 cents compared with 109.7 cents a year earlier.
Adjusted earnings were A$250 million, or 121.7 cents per share, lower than 131.3 cents per share a year ago, indicating that while top-line and underlying profitability improved, some adjustments weighed on the metric investors often track alongside EBITDA.
Underlying EBITDA increased 5.0% to A$614 million. Revenue rose 9.9% to A$13.487 billion, from A$12.267 billion in the prior year—an increase the market appeared to treat as consistent with the company’s broader growth strategy across healthcare distribution and related services.
On shareholder returns, EBOS declared a final dividend of NZ 61.5 cents per share, in line with the prior year. The company set the record date for August 28 and scheduled payment for September 18.
How investors may read the outlook
EBOS’ guidance implies continued profit momentum, with the underlying EBITDA range pointing to steady expansion rather than a one-off recovery. The company’s emphasis on utilisation and productivity suggests management expects benefits from existing distribution and operating networks, while retail pharmacy and medical technology growth points to continued demand for its mix of products and services.
Investors also received a capital-savings message. By expecting lower capital expenditure after the distribution centre renewal program concludes, EBOS is positioning for an environment where incremental earnings may be achieved with less ongoing investment—an area that can matter for valuation when markets focus on medium-term cash conversion.
The company added that, consistent with fiscal 2026, earnings and cash flows are weighted to the second half. EBOS linked that pattern to “normal seasonal trading patterns and working capital movements,” a reminder that quarterly comparisons may be distorted by seasonality and cash flow timing even if annual totals track expectations.
Bigger picture and what to watch next
EBOS’ update comes with a clear mix of growth levers—distribution efficiency, retail expansion, medical technology expansion and animal care growth—alongside a capital expenditure reset after a multi-year program. With the shares jumping following the results and guidance, investors will likely look to confirm that underlying EBITDA delivery aligns with the A$635 million to A$655 million range over the course of fiscal 2027.
Next, the market will monitor EBOS’ quarterly trading into the second half as seasonality and working capital swings come into focus, alongside any updates on capex and the pace of earnings expansion in its retail, medical technology and animal care businesses. Upcoming company communications and broader healthcare and retail demand trends may further shape sentiment as investors assess whether the outlook translates into steady earnings and cash flow.
